Table 1.
Main characteristics of published phase I-II studies assessing immunotherapy antibodies in NSCLC.
| References | Date | Phase | N patients | Target | Drug | Setting | Schedule/dose | RR | mPFS | MST |
|---|---|---|---|---|---|---|---|---|---|---|
| Brahmer et al. (12) | 2010 | I | 39 (6 NSCLC) | PD1 | Nivolumab (MDX-1106) | >1 line | 0.3–10 mg/kg | 7.7% (whole group) | – | – |
| Topalian et al. (13) | 2012 | I | 296 (122 NSCLC) | PD1 | Nivolumab | >1 line | 0.3–10 mg/kg/2 w | Squamous 33% Non-squamous12% |
24 w: 22–33% | – |
| Brahmer et al. (14) | 2012 | I | 207 (75 NSCLC) | PDL1 | BMS-936559 | >1 line | 0.3–10 mg/kg/2 w | 10.2% | 24 w : 31% | – |
| Gettinger et al. (15, 16) | 2015 2018 |
I | 129 | PD1 | Nivolumab | >1 line | 1–10 mg/kg/2 w | Squamous 17% Non-squamous18% |
2.3 m | 9.9 m 5 y16% |
| Garon et al. (17) Hui et al. (18) |
2015 2017 |
I | 495 (101 1st line) | PD1 | Pembrolizumab | Any line | 2–10 mg/kg/3 w 10 mg/kg/2w |
19.4% (26.7%) | 3.7 m (6.2 m) | 12 m (22.1 m) |
| Rizvi et al. (19) | 2015 | II | 117 squamous | PD1 | Nivolumab | >2 lines | 3 mg/kg/2 w | 14.5% | 1.9 m | 8.2 m |
| Garassino et al. (20) | 2018 | II | 444 | PDL1 | Durvalumab | >2 lines | 10 mg/kg/2 w | 3.6–30.9% | 1.9–3.3 m | 9.9–13.3 m |
| Antonia et al. (21) | 2016 | Ib | 102 | PDL1 CTLA4 |
Durvalumab Tremelimumab |
Any line | 3–10–15–20 mg/kg/4 w; 10 mg/kg/2 w 1–3–10 mg/kg/4 w (6 doses), then every 12 weeks (3doses) |
17% | – | – |
| Hellman et al. (22) | 2017 | I | 78 | PD1 CTLA4 |
Nivolumab Ipilimumab |
1st line | Nivo 3 mg/kg/2 w + ipi 1 mg/kg/12 w Nivo 3 mg/kg/2 w + ipi 1 mg/kg/6w |
47% 38% |
8.1 m 3.9m |
1 y– 1 y69% |
| Kanda et al. (23) | 2016 | Ib | 24 | PD1 | Nivolumab + CT | 1st line or ≤ 2 | 10 mg/kg/3 w | 16.7–100% | 3.15 m – NR | – |
| Liu et al. (24) | 2018 | Ib | 76 | PDL1 | Atezolizumab + CT | 1st line | 15 mg/kg/3 w (1,200 mg/3 w) | 36–68% | 5.7–8.4 m | 12.9–18.9 m |
| Forde et al. (25) Bott et al. (26) |
2018 | I | 21 | PD1 | Nivolumab neoadjuvant before surgery | 1st line | 3 mg/kg/2 w twice | 10% Major pathological response45% |
– | |
| Yi et al. (27) Yang et al. (28) |
2017 2018 |
II | 24 | CTLA4 | CDDP/CBDCA-PTX-ipilimumab neoadjuvant before surgery | 1st line | 10 mg/kg cycles 2–3 of chemotherapy | 58% | – | 29.2 m |
RR, response rate; mPFS, median progression free survival; MST, median survival time; NSCLC, non-small cell lung cancer; w, week; m, months; y, year; CT, chemotherapy; NR, not reached; CDDP, cisplatin; CBDCA, carboplatin; PTX, paclitaxel.